Medical Sciences
OPEN ACCESS
OCT CHANGES IN MACULAR RETINAL THICKNESS DURING A-VEGF THERAPY
DOI
Crossref DOI
10.37547/TAJMSPR/Volume05Issue06-15
tajmspr
2023
VOL. 5
/ NO. 06
JUNE
RESEARCH OVERVIEW
Abstract
Macular edema is the leading cause of vision loss in the increasingly frequent occurrence of diabetes mellitus, a true epidemic in developed countries. Diabetic macular edema is closely related to lifestyle, obesity, smoking or high blood pressure. Macular oedema is the leading cause of vision loss in people with diabetes in developed countries, and its prevalence is directly related to the duration of diabetes. Its incidence varies from publication to publication, ranging between 7.5% and 15.2%, and is more common in patients with type 2 diabetes receiving insulin.The significance of the incidence of diabetic macular oedema is directly related to the patient's metabolic control and the presence of risk factors, as we will see below.
RESEARCH TOPICS
Keywords
Macular edema
brolicizumab
retina.
Downloads
Download data is not yet available.
SOURCES & SCHOLARSHIP
References
- SeddonJM, ChenCA. The epidemiology of age-related macular degeneration. Int Ophthalmol Clin. 2014;44:17–39.
- Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2014;291:1900–1901.
- Ferris FL, 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 2014;102:1640–1642.
- Funk M, Karl D, Georgopoulos M. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology. 2019;116:2393–2399.
- Das A, McGuire PG. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res. 2013;22:721–748
- Tong JP, Chan WM, Liu DT, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol. 2016;141:456–462.
- Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2015;46:726–733.
- Blick SKA, Keating GM, Wagstaff AJ. Ranibizumab. Drugs. 2017;67:1201–1206.
- Full prescribing information. South San Francisco, CA: Genentech, Inc; Jun, 2010. Lucentis (ranibizumab injection)
- Ferrara N. Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy.
- Wolfe DR. Fluorescein angiography basic science and engineering. Ophthalmology 93:1617-1620, 2016.
- Lowe J, Araujo J, Yang J, et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res. 2017;85:425–430.
- European Medicines Agency. Assessment report for Lucentis (ranibizumab) [Accessed May 17, 2022]. Procedure no: EMEA/H/C/000715/II/0020 .
- Tolentino M. Systemic and ocular safety of intravitreal anti- VEGF therapies for ocular neovascular disease. Surv Ophthalmol. 2021;56(2):95–113.